Lupin gets USFDA nod to market generic antifungal tablets

New Delhi: Pharma major Lupin Ltd on Monday said it has received approval from the US health regulator to market its generic Fluconazole tablets used in the treatment of fungal infections. The approval granted by the US Food and Drug Administration (USFDA) for the abbreviated new drug application of Fluconazole tablets in strengths of 50 mg, 100 mg, 150 mg and 200 mg, Lupin said in a regulatory filing.

These are the generic equivalents of Diflucan tablets, 50 mg, 100 mg, 150 mg, and 200, Lupin said in a regulatory filing.

These are the generic equivalents of Diflucan tablets, 50 mg, 100 mg, 150 mg, and 200 mg, of Pfizer Inc, it added.

This product will be manufactured at Lupin’s Pithampur facility in India, the company said.

Read more


To Top

As per the rules of the Bar Council of India, lawyers and law firms are not permitted to solicit work or advertise. By clicking on the "I Agree" button, you acknowledge and confirm that you are seeking information relating to Abacus Legal Group (ALG) of your own accord and there has been no advertisement, personal communication, solicitation, invitation or any other inducement of any sort whatsoever by or on behalf of ALG or any of its members to solicit any work through this website.